Positron emission mammography (PEM) has higher detection sensitivity for breast cancer compared with whole-body positron emission tomography (PET) due to higher spatial resolution. We have developed a new PEM device with high resolution over a wide field of view. This PEM device comprises novel scintillation crystals, praseodymium-doped lutetium aluminum garnet (Pr:LuAG). In the present study, the clinical use of the newly developed PEM for the detection of small breast cancer was compared with that of the conventional PET-computed tomography (PET/CT). Eighty-two patients with breast cancer less than 20 mm (UICC T1) participated in this study, including 23 patients with T1a or T1b breast cancer (less than 10 mm). Histologically-proved lesions were examined by PET/CT and PEM on the same day after injection of [
Introduction
Positron-emission tomography-computed tomography (PET/CT) is effective in screening a metastatic lesion or relapse of breast cancer, but its usefulness in the diagnosis of primary lesions has not been elucidated (Fuster et al. 2008; Groheux et al. 2008 Groheux et al. , 2013 Groheux 2017) . In the recent years, improved PET devices with a higher resolution have been developed. Particularly, the breast-dedicated positron emission mammography (PEM) has been reported to have a better sensitivity to a tumor that is 10 mm or smaller in size than that of PET/CT (Rosen et al. 2005; Berg et al. 2006; Eo et al. 2012; Koo et al. 2013; Kalinyak et al. 2014) . Most often used crystals for detection of annihilation radiation are Lutetium Yttrium Orthosilicate (LYSO), Bismuth germanium oxide (BGO) and Gadolinium oxyorthosilicate (GSO). A research group from the Tohoku University collaboratively developed a high-resolution PEM device with two opposed detectors that utilizes new scintillation crystals praseodymium-doped lutetium aluminum garnet (Pr:LuAG) . Its clinical experience for the detection of small breast cancer was not reported until now. The clinical utility of this new device was compared to that of a conventional PET/CT in patients with a UICC T1 tumor that is 20 mm or smaller in size, along with the evaluation of clinical and pathological findings.
Methods

Newly developed high-resolution PEM with an opposed detector
The PEM (PEMGRAPH; Furukawa Co., Ltd., Tsukuba, Japan), used in the present study, utilizes a pair of opposing planar detectors (23 cm × 35 cm in exterior appearance, 14 × 20 cm effective field of view) to capture annihilation photons from the breast. This device uses 10240 rectangular Pr:LuAG crystals (dimension of each crystal is 2.1 × 2.1 × 15.0 mm) and 24 units of position-sensitive photomultiplier tube (PSPMT, Hamamatsu Photonics Co., Ltd., Hamamatsu, Japan). The breast is gently compressed using a detachable and adjustable plastic plate placed between the detectors. Unlike X-ray mammography (MMG), the compression is made with a small pressure of around 50 N to hold the breast to reduce the movement due to respiration and squeeze the breast tissues into the field of view as much as possible. Although the defection of the lines of response (LOR) is unavoidable, a statistical reconstruction technique, maximum likelihood-expectation maximization (ML-EM), was employed to obtain an image at a practical level. The spatial resolution is 2.1 mm (full width at half maximum, FWHM) in the plane parallel to the detectors and the radioactive sensitivity is 9.0 cps/kBq Watanabe et al. 2018) .
Patients
The subjects are comprised of eighty-two patients with invasive breast cancer having a tumor that is 20 mm or smaller in size (T1), referred to the Department of Breast Surgery, KKR Tohoku Kosai Hospital between October 2015 and March 2017. Both PET/CT and PEM were performed to assess tumor extents as preoperative investigations. The PEM images of breast cancer patients were compared with the PET/CT images referring to clinic-pathological findings (Table 1) . Breast cancer diagnosis was made pathologically either by fine needle aspiration under ultrasound (US) or mammotome biopsy. Around 3 weeks after the diagnosis, the patients were referred to Sendai Medical Imaging Clinic to be examined with PET/CT and the newly-developed PEM of Pr:LuAG. A written informed consent was obtained from all the patients separately at both of KKR Tohoku Kosai Hospital and Sendai Medical Imaging Clinic on this study.
Imaging with PET/CT and PEM
After at least five hours fasting, [
18 F]FDG) (3.8 MBq/kg) was administered intravenously via the cubital vein, and a whole-body scan with PET/CT (Siemens Biograph 16; Jakoby et al. 2009 ) was acquired at 75 min after the FDG injection. After whole body CT, from head to pelvis, threedimensional (3D) PET acquisition was done for 2 min per bed position. PET data were acquired using matrix of 128 × 128 pixels with a slice thickness of 3 mm. CT-based attenuation correction of the emission images was used. PET images were reconstructed by iterative ordered subset expectation maximization (OSEM; four iterations and eight subsets) using 5 mm Gaussian kernel. In this setting the PET spatial resolution was approximately 7 mm FWHM. After PET/CT scan the PEM scan was consecutively performed at around 100 min after the FDG injection at 3-5 min duration in the mediolateral (ML) direction with 15 cm detector separation. Imaging with 20 cm detector separation is added to have wider field of view of the chest wall (tangential chest wall scan) in case of thin breast or when the tumor is located in the margin of the breast. The PET/CT and PEM images were independently evaluated by two radiologists/nuclear medicine physicians. Visibility of breast cancer was defined as positive when an isolated hot spot is visually identified exactly at the location pointed out by ultrasound using both the quadrant and clock face notation and the distance from the nipple.
The present PET/CT and PEM study was conducted with the approval of both of the ethics committees of KKR Tohoku Kosai Hospital and Sendai Medical Imaging Clinic. This study was also approved by the Ethics Committee of Tohoku University Graduate School of Medicine (No.2017-1-413) and performed in accordance with the Declaration of Helsinki.
Statistical analysis
The use of standardized uptake value (SUV) is now common place in clinical FDG-PET/CT oncology imaging. For the PEM studies, the semi-quantitative the maximum PEM-uptake value (PUV) was calculated using the following formula: tissue concentration (mCi/g) × body weight (g) / injected FDG dose (mCi). This formula is the same as SUV, but tissue attenuation of photons by breast tissue is not corrected in the PEM examination. The relationship between the tumor/background (T/B) ratio of PET/CT and PEM was examined using Pearson's correlation test. The T/B ratios of PET/CT and PEM were analyzed by both of paired t-test and Wilcoxon single-ranks test. The PUVs among the pathological findings of luminal type, HER2 type and Triple Negative Group (TNG) type were examined by Kruskal-Wallis test for multiple non-parametric comparisons. The difference in PUVs between the degree of pathological malignancy was examined using a non-parametric Mann-Whitney's U test. The level of statistical significance was set at p < 0.05. All statistical analyses were performed on BellCurve for Excel (BellCurve BU, Tokyo, Japan). Table 1 shows the characteristics of the 82 patients with invasive breast cancer whose tumor is 20 mm or smaller in size (T1), summarizing tumor detectability with either PET/CT or PEM or both combined performed before surgery in KKR Tohoku Kosai Hospital between October 2015 and March 2017. Fig. 1 depicts a representative case of an invasive ductal carcinoma (13 × 9 × 8 mm in size) that was detected via medical screening. The MMG pointed out a focal asymmetric density (FAD) of category 3, in the upper outer C quadrant with a high FDG uptake in both PET/CT and PEM images. The sensitivity and resolving power of the newly developed PEM are 2-3 times higher than those of conventional PET/CT (Siemens Biograph). Other examples that show the superiority of PEM over PET/CT are presented in Fig. 2 . In Fig. 2A , a small breast tumor of 4 mm in size with ultrasound was clearly depicted with PEM which were not detectable with PET/CT. In Fig.  2B , small hot nodules more than three in number, were resolved with PEM while only a single tumor was visible with the PET/CT. Fig. 3 shows the relationship between PET/CT and PEM as assessed by the T/B ratio at the tumor site. The correlation coefficient (R²) was 0.64 in all patients with a T1 lesion and 0.87 in patients with T1a/1b lesion (less than 10 mm), both showing a favorable correlation (Pearson's correlation coefficient test; P < 0.0001). In all patients with a T1 lesion, the mean T/B ratio was 3.8 ± 3.6 in PET/CT and 3.3 ± 2.1 in PEM, showing no statistical difference (paired t-test and Wilcoxon single-ranks test: p > 0.1). In patients with T1a/1b lesions, the mean T/B ratio was 1.6 ± 0.9 in PET/CT and 2.3 ± 2.0 in PEM, showing that PEM was significantly higher than PET (paired t-test and Wilcoxon single-ranks test: p < 0.01). This result reflects the fact that PEM has better sensitivity of cancer detection than PET/CT in the small T1a/1b lesions because of its higher resolution. Table 2 shows the detection rate of PEM and PET/CT in all T1 (82 cases). In all patients with a T1 lesion, the detection sensitivities of PET/CT, PEM, and PET/CT and PEM were 82%, 85%, and 90%, respectively, showing no statistical difference. However, the diagnostic sensitivity slightly increased when used PET and PEM together. In 23 patients with a T1a/1b lesion that is smaller than T1c (10 mm < tumor size ≤ 20 mm), the detection sensitivities of PET/CT, PEM, and PET/CT and PEM were 48%, 65%, and 70%, respectively, showing a similar result (Table 3) . Most of the cases in which a lesion was detectable with PEM but was undetectable with PET/CT were categorized in T1a/1b cases. All cases in which a lesion was not detectable with PEM are those with regions of upper inner quadrant A.
Results
Utility of the newly developed PEM
Comparison of the performance of PET/CT and PEM to detect breast cancer
Pathological findings and PUV
The pathological findings and PUV obtained before surgery were compared. As shown in Fig. 4 , when the PUV was compared based on subtype, the average PUV of the luminal type A+B, HER2 type, and TNG type were 3.3 ± 1.8, 3.9 ± 1.0, and 4.7 ± 1.4 (mean ± SD), indicating that the PUV increases in the order of Luminal A+B < HER 2 type < TNG. Moreover, a slight difference was observed among these 3 subtypes (Kruskal-Wallis test: P = 0.035). Fig. 5 shows the relationship between the degree of pathological malignancy and the PUV. The PUV was 3.0 ± 1.7 (mean ± SD) in Nuclear grade (NG) 1-2 and 4.4 ± 1.8 in NG3, showing a significant difference ( Fig. 5A ; MannWhitney's U test P < 0.01). When a cutoff value of 20 was used for Ki-67, the PUV was 3.1 ± 1.8 (mean ± SD) in Ki-67 of < 20 and 4.1 ± 1.5 in Ki-67 of ≥ 20, showing a significant difference ( Fig. 5B ; Mann-Whitney's U test P < 0.01). In other words, these results indicate that the PUV increases with the degree of malignancy.
Discussion
A research group from the Tohoku University and Furukawa Co., Ltd. collaboratively developed a high-resolution PEM device with opposed detectors that utilizes new scintillation crystals of Pr:LuAG, which has not been used before for PET or PEM. Pr:LuAG has almost twice as shorter scintillation decay time than that of LYSO . Pr:LuAG is expected to produce PEM images with a better signal-to-noise ratio in high count rate study as compared to the commonly used LYSO. Yoshikawa et al. (2010) evaluated the clinical utility of PEMGRAPH for the diagnosis of breast cancer lesions that are 20 mm or smaller in size. Characteristically, the newly developed PEM has better radiation sensitivity than conventional PET/CT, which may reduce the amount of FDG injection. In addition, the newly-developed PEM has a high resolution similar to other commercially-available PEM scanners (Caldarella et al. 2014) . Another benefit of PEM is that no extra radiation is required for the study when PEM is carried out sequentially after PET/CT examination.
In the present study, the T/B ratio of a tumor that is 10 mm or smaller in size (T1a/1b cases) was significantly higher in PEM than in PET/CT. Most of the cases in which a lesion was detectable with PEM but was undetectable with PET/CT were categorized in T1a/1b cases, suggesting the good utility of PEM in the detection of a tumor that is 10 mm or less. Concerning the location of the tumor in the breast, tumors in the upper inner quadrant, quadrant A, were most difficult to be identified with PEM followed by the lower inner quadrant, quadrant B. The breast areas close to the sternum must be blind areas for PEM. Therefore, we employed the chest-wall scan that is a tangential imaging of breast tissue opening the detector distance up to 20 cm. The chest-wall scan may be a solution to reduce blind breast areas although the spatial resolution is lost in some extent along the direction perpendicular to the detectors as shown in Fig. 6 . The specificity of PEM was reported to be better than that of MRI (Caldarella et al. 2014) . We need further studies to mention on this topic. However, based on the present study of PEM, we need to gather the data of the patients who underwent both PET/CT and PEM before preoperative histological biopsy because the detectability of the small tumors with further PET/CT or PEM decreases after biopsy.
A significantly higher PUV was observed in cases with NG-3 and Ki-67 ≥ 20, suggesting that a good correlation between glucose metabolism and the nuclear grade score and Ki-67. These results were supported by the comparison of the subtypes wherein the highly malignant triple negative type often had a high PUV, while the less malignant luminal The appearance of the newly-developed PEM device is shown. The distance between the detectors can be adjusted from 5 cm to 25 cm. The area of visualization can be increased by some adjustments to include the tumors residing in the region proximal to the chest wall or in the thin breast.
types had a low PUV. Thus, the estimation of the degree of malignancy may be made with PEM imaging especially in the early stage of breast cancer taking advantage of high resolution (Basu et al. 2008; Groheux et al. 2011; Bitencourt et al. 2017) . In addition, the use of other probes may be useful for the future applications PET/CT and PEM. It is reported that 18 F-fluoroestradiol (estrogen receptor binding) and 68 Ga-ABY025 (HER2-binding affibody) can predict the therapy responses (Peterson et al. 2014; Sörensen et al. 2016; Kurland et al. 2017) .
Because the detection rate of breast cancer with wholebody PET/CT screening health check was reported to be 0.18%-0.23% of healthy population, the use of PET/CT is not recommended as a screening method for breast cancer. With an improved resolution of PEM, some research showed that the detection rate of PEM was 2.3%, which is better than that of PET/CT (Yamamoto et al. 2015 (Yamamoto et al. , 2016 . Other research suggested that the sensitivity of PEM is significantly better than that of PET in tumors that are 20 mm or smaller in size (Eo et al. 2012) .
Using the newly-developed PEM device that utilizes scintillation crystals of Pr:LuAG, Watanabe et al. (2018) demonstrated that resected specimen-PEM examination delineated tumor extension in breast-conserving surgery. The results of our study have following limitations. Because of the small sample size, some statistical analyses could have been affected. On the other hand, the present study has demonstrated that the sensitivity is better with PEM for tumors that are 10 mm or smaller in size. However, in all tumors, no significant difference was observed in the tumor detection sensitivity of PEM and PET/CT in UICC T1 cases. One of drawbacks of the present study is that we evaluated tumor FDG uptake by one or zero, that is detected or not detected. Further studies are needed taking account of count recovery of FDG uptake in tumors that is crucially affected by the spatial resolution.
The detection rate and accuracy can be improved by using both PET/CT and PEM combined over whole-body PET/CT alone. PET/CT is useful to assess tumor spreads in the whole body, while PEM can be used to assess tumor extent and spreads within the breast in a synergic and complimentary manner. Considering that the resolution of PEM can be further improved using smaller scintillation crystals and larger numbers of electronics, new PEM techniques may reach metabolic and pathological imaging of tumors with less than 10 mm. Further studies correlating PEM imaging, pathological and molecular features could help us to better understanding of breast cancers and their tissue heterogeneity that leads to proper personalized management of breast cancer.
